Predictors of outcome in children with Langerhans cell histiocytosis

Pediatric Blood and Cancer

Volumn 45, Issue 1, 2005, Pages 37-42

  Jubran, Rima F ^a,b   Marachelian, Araz ^a   Dorey, Frederick ^a   Malogolowkin, Marcio ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE DISEASE; CHILDHOOD MORTALITY; DISEASE COURSE; DISEASE SEVERITY; ENDOCRINE DISEASE; HISTIOCYTOSIS X; HUMAN; LEG LENGTH INEQUALITY; MORBIDITY; NEUROLOGICAL COMPLICATION; ORTHOPEDICS; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SHORT STATURE; SKULL DISEASE; SURVIVAL TIME;

ADOLESCENT; ADULT; BONE DISEASES; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; INFANT; LOS ANGELES; MALE; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 20344383983     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20364     Document Type: Review

References (29)

1. Ladish S, Jaffe ES. The histiocytoses. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology, 4th edition. Philadelphia: Lippincott; 2002. pp 733-747.
2. Arico M, Egeler M. Clinical aspects of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998;12:247-258.
3. Willman CL, Busque L, Griffith BB, et al. Langerhans'-cell histiocytosis (histiocytosis X)-A clonal proliferative disease. N Engl J Med 1994;331:154-160.
4. Pritchard J, Broadbent V. Histiocytosis - An introduction. Br J Cancer 1994;70:S1-S3.
5. Nezwlod C, Basset F, Roussea MF. Histiocytosis X; Histogenic arguments for a Langerhans' cell origin. Biomedicine 1973;18: 365-371.
6. Cline MJ. Histiocytes and histiocytosis. Blood 1994;84:2840-2853.
7. Egeler RM, D'Angio GJ. Langerhans cell histiocytosis. J Pediatrics 1995;127:1-11.
8. Komp DM. Langerhans cell histiocytosis. N Engl J Med 1987;316: 747-748.
9. Broadbent M, Egler M, Nesbit ME. Langerhans cell histiocytosis-Clinical and epidemiological aspects. J Cancer 1994;70:S11-S16.
10. Chu T, D'Angio GJ, Favara B, et al. Histiocytosis syndromes in children. Lancet 1987;306:208-209.
11. Minkov M, Grois N, Heitger A, et al. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group. Klin Pediat 2000;212: 139-144.
12. Ladisch S, Gadner H, Arico M, et al. LCH-I: A randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis. Med Pediatr Oncol 1994;23:107-110.
13. Broadbent V, Gadner H. Current therapy for Langerhans cell histiocytosis. Hematol/Oncol Clin N Am 1998;12:327-335.
14. Minkov M, Grois N, Heitger A, et al. Response to initial treatment of multisystem Langerhans cell histiocytosis: An important prognostic indicator. Med Pediatr Oncol 2002;39:581-585.
15. Imashuku S, Ishida S, Koike K, et al. Cerebellar ataxia in pediatric patients with Langerhans cell histiocytosis. J Pediatr Hematol Oncol 2004;26:735-739.
16. Weitzman S, Wayne A, Arceci R, et al. Nucleoside analogues in the therapy of Langerhans cell histiocytosis: A survey of members of the histiocyte society and review of the literature. Med Pediatr Oncol 1999;33:476-481.
17. Pardanani A, Phyliky RL, Li CY, et al. 2-Chlorodeoxyadenosine therapy for disseminated Langerhans cell histiocytosis. Mayo Clin Proc 2003;78:301-306.
18. Rodrigeuz-Galindo C, Kelly P, Jeng M, et al. Treatment of children with Langerhans cell histiocytosis with 2-chlorodeoxyadenosine. Am J Hem 2002;69:179-184.
19. Choi SW, Bangaru BS, Wu CD, et al. Gastroinstestinal involvement in disseminated Langerhans cell histiocytosis (LCH) with durable complete response to 2-chlorodeocyadenosine and high-dise cytarabine. J Pediatr Hematol Oncol 2003;25:503-506.
20. Greinic HT, Storb R, Sanders JE, et al. Marrow transplantation for treatment of multisystem progressive Langerhans cell histiocytosis. Bone Marrow Transplant 1992;10:39-44.
21. Ringden O, Ahstrom L, Lonnquest B, et al. Allogeneic bone marrow transplant with chemotherapy resistant progressive histiocytosis X. N Engl J Med 1987;316:733-747.
22. Hale GA, Bowman LC, Woodard JM, et al. Allogeneic bone marrow transplantation for children with histiocytic disorders: Use of TBI and omission of etoposide in the conditioning regimen. Bone Marrow Transplant 2003;31:981-986.
23. Akkari V, Donadieu C, Piguet P, et al. Hematopoietic stem cell transplantation in patients with sever Langerhans cell histiocytosis and hematological dysfunction: Experience of the French Langerhans Cell Study Group. Bone Marrow Transplantation 2003;31: 1097-1103.
24. Ghanem I, Tolo V, D'Ambria P, et al. Langerhans cell histiocytosis of bone in children and adolescents. J Pediatr Orthop 2003;23:124-130.
25. Kusumakumary P, James FV. Permanent diabilities in childhood survivors of Langerhans cell histiocytosis. Pediatr Hematol Oncol 2000;17:375-381.
26. Grois N, Flutcher-Wolfran B, Hietger A, et al. Diabetes insipidus in Langerhans cell histiocytosis: Results from the DAL-HX83 study. Med Pediatr Oncol 1995;24:248-256.
27. Prosch H, Grois N, Prayer D, et al. Central diabetes insipidus as presenting symptom of Langerhans cell histiocytosis. Pediatr Blood Cancer 2004;43:594-599.
28. Nanduri VR, Bareille P, Pritchard J, et al. Growth and endocrine disorders in multisystem Langerhans cell histiocytosis. Clin Endocrinol (Oxf) 2000;53:509-515.
29. Donadieu J, Rolon M, Thomas C, et al. Endocrine involvement in pediatric-onset Langerhans cell histiocytosis: A population-based study. J Pediatr 2004;144:344-350.